DUBLIN–(BUSINESS WIRE)–The “Global Transdermal Drug Delivery Systems Market Analysis 2019” report has been added to ResearchAndMarkets.com’s offering.
The Global Transdermal Drug Delivery Systems market is expected to reach $9.29 billion by 2026 growing at a CAGR of 6.3% during the forecast period.
Increasing prevalence of chronic diseases, technological advancements in transdermal drug delivery systems, and growing geriatric population along with the rise in prevalence of chronic diseases across the world are some of the factors fuelling the market growth. However, disadvantages of delivery systems including edema and irritation, natural limits of drug entry imposed by the skin’s impermeability, and lack of adhesion of the transdermal system to different skin types are hampering the market growth.
Based on the application, the pain management segment is likely to have a huge demand due to elevating burden of chronic pain globally and the growing availability of transdermal products for pain management.
The key vendors mentioned are UCB S.A., Hisamitsu Pharmaceutical Co., Inc., Glaxosmithkline PLC, Johnson & Johnson (J&J), Mylan N.V., Boehringer Ingelheim International GmbH, Novartis AG, Lavipharm, Endo International, Inc., Luye Pharma Group, Purdue Pharma L.P., Lead Chemicals Co., Inc., Pfizer Inc., Allergan Plc, Actelion Pharmaceuticals Ltd, Noven Pharmaceuticals, Inc., Echo Therapeutics, Inc., Boehringer Ingelheim Gmbh, Bayer Ag, and Acrux Limited.
Key Questions Answered in this Report
- How this market evolved since the year 2016
- Market size estimations, forecasts and CAGR for all the segments presented in the scope
- Key Market Developments and financials of the key players
- Opportunity Analysis for the new entrants
- SWOT Analysis of the key players
- Fastest growing markets analysed during the forecast period
Key Topics Covered
1 Market Synopsis
2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
2.3.1 Primary Research Sources
2.3.2 Secondary Research Sources
3 Market Dynamics
4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Transdermal Drug Delivery Systems Market, By Technology
5.3 Electric Current
5.10 Mechanical Arrays
5.11 Other Technologies
6 Global Transdermal Drug Delivery Systems Market, By Product Type
6.5 Other Product Types
7 Global Transdermal Drug Delivery Systems Market, By Type
7.2 Transdermal Semisolids/Active
7.3 Transdermal Patches/Passive
8 Global Transdermal Drug Delivery Systems Market, By Application
8.2 Hormonal Applications
8.3 Cardiovascular Diseases
8.4 Central Nervous System Disorders
8.5 Pain Management
8.6 Smoking Cessation
8.9 Motion Sickness
9 Global Transdermal Drug Delivery Systems Market, By End-user
9.2 Hospitals & Clinics
9.3 Home Care Settings
9.4 Surgical Centers
9.5 Other End-users
10 Global Transdermal Drug Delivery Systems Market, By Geography
10.2 North America
10.5 South America
10.6 Middle East & Africa
11 Strategic Benchmarking
12 Vendors Landscape
12.1 UCB S.A.
12.2 Hisamitsu Pharmaceutical Co. Inc.
12.3 Glaxosmithkline PLC
12.4 Johnson & Johnson (J&J)
12.5 Mylan N.V.
12.6 Boehringer Ingelheim International GmbH
12.7 Novartis AG
12.9 Endo International, Inc.
12.10 Luye Pharma Group
12.11 Purdue Pharma L.P.
12.12 Lead Chemicals Co. Inc.
12.13 Pfizer Inc.
12.14 Allergan PLC
12.15 Actelion Pharmaceuticals Ltd.
12.16 Noven Pharmaceuticals, Inc.
12.17 Echo Therapeutics, Inc.
12.18 Boehringer Ingelheim GmbH
12.19 Bayer AG
12.20 Acrux Limited
For more information about this report visit https://www.researchandmarkets.com/r/hqpoll
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900